

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 10:25:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        3 TO ITERATE

100.0% PROCESSED         3 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            3 TO      163
PROJECTED ANSWERS:               3 TO      163

L5             3 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 10:25:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       56 TO ITERATE

100.0% PROCESSED        56 ITERATIONS                               56 ANSWERS
SEARCH TIME: 00.00.01

L6            56 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 323.09     323.30

FILE 'CAPLUS' ENTERED AT 10:25:40 ON 15 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is

FILE COVERS 1907 - 15 Nov 2005 VOL 143 ISS 21
FILE LAST UPDATED: 14 Nov 2005 (20051114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 10 L6

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:704222 CAPLUS
DOCUMENT NUMBER: 143:326257
TITLE: Theoretical and Experimental Design of Atypical Kinase Inhibitors: Application to p38 MAP Kinase
AUTHOR(S): McClure, Kim F.; Abramov, Yuriy A.; Laird, Ellen R.; Barberia, John T.; Cai, Weiling; Carty, Thomas J.; Cortina, Santo R.; Danley, Dennis E.; Dipesa, Alan J.; Donahue, Kathleen M.; Dombroski, Mark A.; Elliott, Nancy C.; Gabel, Christopher A.; Han, Seungil; Hynes, Thomas R.; LeMotte, Peter K.; Mansour, Mahmoud N.; Marr, Eric S.; Letavic, Michael A.; Pandit, Jayvardhan; Ripin, David B.; Sweeney, Francis J.; Tan, Douglas; Tao, Yong
CORPORATE SOURCE: Groton Laboratories, Pfizer Global Research and Development, Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(18), 5728-5737
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

II

AB Mimics of the benzimidazolone nucleus found in inhibitors of p38 kinase are proposed, and their theor. potential as bioisosteres is described. A set of calculated descriptors relevant to the anticipated binding interaction for the fragments 1-methyl-1H-benzotriazole, 3-methylbenzo[d]isoxazole, and 3-methyl[1,2,4]triazolo[4,3-a]pyridine, pyridine, and 1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one are reported. The design considerations and synthesis of p38 inhibitors based on these H-bond acceptor fragments is detailed. Comparative evaluation of the pyridine-, benzimidazolone-, benzotriazole-, and triazolopyridine-based inhibitors shows the triazoles I and II to be significantly more potent exptl. than the benzimidazolone after which they were modeled. An X-ray crystal structure of II bound to the active site shows that the triazole group serves as the H-bond acceptor but unexpectedly as a dual acceptor,

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
inducing movement of the crossover connection of p38α. The computed descriptors for the hydrophobic and π-π interaction capacities were the most useful in ranking potency.
IT 459447-77-9DP, complex with p38 kinase
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (formation and crystal structure of)
RN 459447-77-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 459447-77-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyridine-, benzimidazolone-, benzotriazole-, and triazolopyridine-based inhibitors for p38 kinase)
RN 459447-77-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:588664 CAPLUS
DOCUMENT NUMBER: 143:91021
TITLE: Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors
INVENTOR(S): Kehrli, Marcus Eugene, Jr.; Sakya, Subas Man
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060967	A1	20050707	WO 2004-IB4035	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005153985	A1	20050714	US 2004-14392	20041216
PRIORITY APPLN. INFO.:			US 2003-530722P P	20031218
OTHER SOURCE(S):		MARPAT 143:91021		

AB The present invention provides methods for treating animals having acute inflammatory conditions, including mastitis, by administering at least one p38 MAP kinase inhibitor. The present invention also provides methods for enhancing milk production and reducing milk discard in animals afflicted with acute inflammatory conditions by administering at least one, p38 MAP kinase inhibitor.
IT 459447-61-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating acute inflammation in animals with p38 MAP kinase inhibitors)
RN 459447-61-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:654777 CAPLUS
DOCUMENT NUMBER: 141:190791
TITLE: Preparation of cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase
INVENTOR(S): Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157877	A1	20040812	US 2003-649216	20030827
PRIORITY APPLN. INFO.:			US 2002-407086P P	20020830
OTHER SOURCE(S):		MARPAT 141:190791		

GI



I



II

AB The title compds. [I; R1 = F; s = 3; R2 = (un)substituted cycloalkyl] which are potent inhibitors of MAP kinases, preferably p38 kinase, and therefore useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders, were prepared E.g., a multi-step synthesis of II, starting from 2,5-dibromopyridine, was given. The pharmaceutical composition comprising the compound I is claimed.
IT 668990-95-2P 668990-96-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)
RN 668990-95-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-96-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



IT 668981-08-6P, 6-[Oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine 668981-09-7P, 6-[4-Bromooxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)
RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 668981-09-7 CAPLUS

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:589283 CAPLUS
DOCUMENT NUMBER: 141:140449
TITLE: Preparation of novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.
INVENTOR(S): Kang, Ming; Li, Zheng Jane; Li, Zhengong Bryan; Tao, Yong
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004143119	A1	20040722	US 2003-649194	20030827
US 6949652	B2	20050927		

PRIORITY APPLN. INFO.: US 2002-407158P P 20020830
AB Crystalline forms of 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (I) having specified x-ray crystallog., 13C solid state NMR, and differential scanning calorimetry data were prepared Thus, N-α-tosyl-(2,5-difluorobenzyl)isocyanide (preparation given), 3-isopropyl-1,2,4-triazolo[4,3-a]pyridine-6-carboxaldehyde (preparation given), and K2CO3 were refluxed together for 22 h in MeCN to give 61% I. This was triturated in EtOAc/hexane followed by drying in vacuo at 40° for 48 h to give I form A.
IT 668981-02-0P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of novel crystalline forms of isopropyldifluorophenyloxazolyltriazol opyridine)
RN 668981-02-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 668981-04-2P 668981-05-3P 668981-07-5P 668981-08-6P 668981-09-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel crystalline forms of isopropyldifluorophenyloxazolyltriazol opyridine)
RN 668981-04-2 CAPLUS

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 668981-05-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 668981-09-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392324 CAPLUS
DOCUMENT NUMBER: 140:406810
TITLE: Preparation of alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolopyridines as MAP kinases, in particular p38 kinase inhibitors
INVENTOR(S): Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092547	A1	20040513	US 2003-649227	20030827
PRIORITY APPLN. INFO.:			US 2002-407088P P	20020830

OTHER SOURCE(S): MARPAT 140:406810
GI



AB Title compds. I [wherein R1 = F; n = 2; R2 = alkyl, optionally substituted by halo, OH, alkoxy, and alkoxycarbonyl; with certain compds. absent; their pharmaceutically acceptable salts] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, II was prepared by Pd-cross coupling of 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (preparation given) with 2,5-difluoroboronic acid in the presence of TEA/EtOH/H2O. Selected I had an IC50 <10 μM in the TNF-α and MAPKAP in vitro assays, and an EC50 <50 mg/kg in the in vivo TNFα assay. I are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

IT **668981-08-6P**, 6-(Oxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-09-7P**, 6-(4-Bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of alkyldifluorophenyloxazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 668981-09-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **668981-02-0P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(p38 kinase inhibitor; preparation of alkyldifluorophenyloxazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)

RN 668981-02-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **459448-00-1P**, 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-04-2P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride **668981-05-3P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
[1,2,4]triazolo[4,3-a]pyridine methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate 668990-77-0P, 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-78-1P, 3-tert-Butyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-97-4P, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; prepn. of alkyldifluorophenyloxazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)
RN 459448-00-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-03-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 7664-93-9
CMF H2 O4 S

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 668981-05-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 668990-77-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 668990-78-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 668990-97-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:372880 CAPLUS
DOCUMENT NUMBER: 140:391284
TITLE: Preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase
INVENTOR(S): Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087615	A1	20040506	US 2003-649255	20030827
PRIORITY APPLN. INFO.:			US 2002-407489P P	20020830

OTHER SOURCE(S): MARPAT 140:391284
GI


I


II

AB The title compds. [I; R1 = F; s = 2; R2 = (un)substituted cycloalkyl] which are potent inhibitors of MAP kinases, preferably p38 kinase, and therefore useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders, were prepared E.g., a multi-step synthesis of II, starting from 2,5-dibromopyridine, was given. The pharmaceutical composition comprising the compound I is claimed.

IT **668990-79-2P**, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)

RN 668990-79-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolyl]- (9CI) (CA INDEX NAME)



IT **668990-83-8P**, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine **668990-84-9P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)[1,2,4]triazolo[4,3-a]pyridine **668990-85-0P**, 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)[1,2,4]triazolo[4,3-a]pyridine **668990-86-1P**, 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)

RN 668990-83-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-84-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-85-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 668990-86-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



IT **668981-08-6P**, 6-[Oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-09-7P**, 6-[4-Bromooxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)

RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668981-09-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)-(9CI) (CA INDEX NAME)



L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:331789 CAPLUS
DOCUMENT NUMBER: 140:357352
TITLE: Preparation of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases
INVENTOR(S): Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004077682	A1	20040422	US 2003-649265	20030827
PRIORITY APPLN. INFO.:			US 2002-407089P P	20020830

OTHER SOURCE(S): MARPAT 140:357352
GI



I



II

AB The title compds. [I; R1 = F; s = 3; R2 = alkyl optionally substituted by halo, OH, alkoxy, etc.] which are potent inhibitors of MAP kinases, preferably p38 kinase, were prepared Thus, reacting [α-(p-toluenesulfonyl)-2,4,5-trifluorobenzyl]isonitrile with 3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxaldehyde (prepns. given) in the presence of K2CO3 in MeCN at 70°C for 22 h afforded 48% II. All compds. I that were tested had an IC50 of <10 μM in the TNFα and MAPKAP in vitro assays and ED50 of <50 mg/kg in the in vivo TNFα assay. The compds. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. The pharmaceutical composition comprising the compound I is claimed.

IT 668990-87-2P 668990-90-7P 668990-91-8P
668990-92-9P 668990-93-0P 668990-94-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases)

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 668990-87-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-90-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,4-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-91-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-92-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,6-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-93-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-94-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1,1-dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



IT 668981-08-6P 668981-09-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases)

RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668981-09-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203834 CAPLUS
DOCUMENT NUMBER: 140:235722
TITLE: Preparation of 6-[4-(di- or trifluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine as inhibitors of mitogen-activated protein (MAP) kinases
INVENTOR(S): Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020440	A1	20040311	WO 2003-IB3847	20030819
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494754	AA	20040311	CA 2003-2494754	20030819
EP 1537108	A1	20050608	EP 2003-791145	20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013965	A	20050719	BR 2003-13965	20030819
US 2004053958	A1	20040318	US 2003-649236	20030827
PRIORITY APPLN. INFO.:			US 2002-407177P P	20020830
			WO 2003-IB3847 W	20030819

OTHER SOURCE(S): MARPAT 140:235722
GI

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB The present invention relates to novel triazolo-pyridines of the formula (I) [wherein R1 is fluoro; m = 2,3; R2 is C3-6 cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-4 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; or R2 is C1-6 alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-6 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; with the proviso that said compound of this formula cannot be 6-[4-(2,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine or 6-[4-(3,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine] or pharmaceutically acceptable salt thereof; to intermediates for their preparation, and to pharmaceutical compns. containing them and to their medicinal use. The compds. I are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, a mixture of [α-(p-toluenesulfonyl)-2,6-difluorobenzyl]isonitrile (1.79 g, 5.84 mmol), 3-isopropyl-[1,2,4]triazolo[4,3-a]-6-pyridinecarboxaldehyde > (1.10 g, 5.84 mmol), potassium carbonate (1.05 g, 7.59 mmol) and acetonitrile (17.5 mL) was refluxed for 22 h to give, after workup and silica gel chromatog., 6-[4-(2,6-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine as a yellow solid. A tablet formulation containing 6-[4-(2,5-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine was prepared, which can be administered to a human from one to four times a day for inhibiting cartilage damage or treating osteoarthritis.

IT **668981-02-0P**
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(X-ray crystalog. data and polymorphism; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-02-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **668981-08-6P**, 3-Isopropyl-6-(oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



IT **668990-79-2P**, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668990-79-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 668981-09-7P, 3-Isopropyl-6-(4-bromooxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)
RN 668981-09-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 668981-03-1P, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine 668981-04-2P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride 668981-05-3P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate 668990-77-0P, 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-78-1P, 3-tert-Butyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine 668990-83-6P, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine 668990-84-9P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine 668990-85-0P, 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine 668990-86-1P, 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-87-2P, 3-Isopropyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-90-7P, 3-Isopropyl-6-[4-(2,3,4-trifluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine 668990-91-8P, 3-Isopropyl-6-[4-(2,3,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-92-9P, 3-Isopropyl-6-[4-(2,4,6-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-93-0P, 3-Isopropyl-6-[4-(3,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-94-1P, 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-95-2P, 3-Cyclopropyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-96-3P, 3-(1-Methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-97-4P, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl][1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)
RN 668981-03-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 668981-05-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 668990-77-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 668990-78-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 668990-83-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-84-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 668990-85-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-86-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-87-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-90-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,4-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-91-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-92-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,6-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-93-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-94-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1,1-dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-95-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-96-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 668990-97-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203832 CAPLUS
DOCUMENT NUMBER: 140:235721
TITLE: Novel processes and intermediates for preparing [1,2,4]triazolo[4,3-a]pyridines
INVENTOR(S): Buzon, Richard Allen Sr.; Castaldi, Michael James; Li, Zhengong Bryan; Ripin, David Harold Brown; Tao, Yong
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020438	A2	20040311	WO 2003-IB3669	20030818
WO 2004020438	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496812	AA	20040311	CA 2003-2496812	20030818
EP 1537107	A2	20050608	EP 2003-791115	20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013961	A	20050719	BR 2003-13961	20030818
US 2004053959	A1	20040318	US 2003-649247	20030827
			US 2002-407085P P	20020830
			WO 2003-IB3669 W	20030818

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): CASREACT 140:235721; MARPAT 140:235721
GI

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The present invention relates and intermediates to a novel process for preparing triazolo-pyridines of the formula (I) [R1 = H, cyano, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl or NH2; R3 = halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, perhalo-C1-6 alkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl, C3-10 cycloalkyl, HO, C1-6 alkoxy, perhalo-C1-10 alkoxy, PhO, C1-10 heteroaryloxy, C1-10 heterocyclyloxy-C3-10 cycloalkyloxy, C1-6 alkylthio, C1-16 alkylsulfonyl, C1-6 alkylsulfamoyl, amino, mono - or di(C1-6 alkyl)amino, C1-6 sulfonylamino, C1-6 alkyl-carbonylamino, etc.; or two adjacent R2 taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; m = an integer from 0-5; R4 = H, F, Cl, R5-B-(CH2)n-; n = n integer from 0-6; B = a bond, (CHR6), O, S, SO2, CO, O-CO, CO-O, CO-NR6, R6N, R6NSO2, R6NCO, SO2NR6, R6NCONR7, O-CONR6 or R6NCO-O; R5 = H, CF3, cyano, each (un)substituted Ph, C1-10 heterocyclyl, C1-10 heteroaryl, or C3-10 cycloalkyl, etc.; R6 = H, C1-6 alkylsulfonyl, C1-6 alkyl] or acceptable salts thereof, e.g., comprising reacting 6-(oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridines (II) (L = a leaving group and R1 and R4 are as defined above) with phenylboronoic acids (III) and a transition metal catalyst. The compds. I prepared by the methods of the present invention are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine (33.0 g, 0.107 mol), 2,5-difluorophenylboronic acid (25.34 g, 0.1605 mol), Pd(PPh3)4 (12.36 g, 0.0107 mol), Et3N (22.37 mL, 0.1605 mol), 2B ethanol (495 mL), and water (33 mL), were added to a 2 L 4 neck round bottom flask (equipped with mech. stirring, nitrogen, heating mantle, temperature controller, and a condenser), stirred while heating to 65 to 70°, and kept stirring overnight at .apprx.70°. Two addnl. difluorophenylboronic acid (8.5 g, 0.054 mol) and Et3N (7.53 mL, 0.054 mol), were added and each time the reaction was allowed to proceed overnight at 70°. Toluene (30 mL) was added and the reaction was allowed to go overnight once again at 70°, treated with H2O (495 mL), and pot-granulated for 4 h at 20 to 25°. The solids were collected by vacuum filtration, washed with 2B ethanol/H2O (50:50) (25 mL of each), and dried in a vacuum oven at 45° for 4 ho under full vacuum to afford 14.4 g 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (40.6% yield, 93.4% purity by HPLC).

IT 668981-08-6P, 6-(Oxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-08-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



IT 668981-09-7P, 6-(4-Bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-09-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-bromo-5-oxazolyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

IT 668981-02-0P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-02-0 CAPLUS

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 668981-03-1P, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine 668981-04-2P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride 668981-05-3P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine sulfate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-03-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 668981-05-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 7664-93-9
CMF H2 O4 S

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:716275 CAPLUS
DOCUMENT NUMBER: 137:232658
TITLE: Preparation of 6-(phenylheterocyclyl)-[1,2,4]triazolo[4,3-a]pyridines as anti-inflammatory agents
INVENTOR(S): Dombroski, Mark Anthony; Duplantier, Allen Jacob; Laird, Ellen Ruth; Letavic, Michael Anthony; McClure, Kim Francis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072579	A1	20020919	WO 2002-IB424	20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440222	AA	20020919	CA 2002-2440222	20020208
EP 1370559	A1	20031217	EP 2002-710260	20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300437	A	20040216	EE 2003-437	20020208
BR 2002007990	A	20040427	BR 2002-7990	20020208
CN 1496366	A	20040512	CN 2002-806282	20020208
JP 2004522799	T2	20040729	JP 2002-571495	20020208
NZ 526528	A	20050225	NZ 2002-526528	20020208
US 2003096838	A1	20030522	US 2002-94760	20020311
US 6696464	B2	20040224		
ZA 2003004983	A	20040629	ZA 2003-4983	20030626
BG 108133	A	20040930	BG 2003-108133	20030825
NO 2003003969	A	20031013	NO 2003-3969	20030908

PRIORITY APPLN. INFO.: US 2001-274840P P 20010309
WO 2002-IB424 W 20020208
OTHER SOURCE(S): MARPAT 137:232658
GI

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I II

AB Title compds. I [wherein Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R2 = H, alkenyl, alkynyl, or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl, or amino; R3 = halo, (cyclo)alkyl(oxy), (perhalo)alkyl, alkenyl, alkynyl, Ph, heteroaryl(oxy), heterocyclyl(oxy), OH, (perhalo)alkoxy, PhO, alkylthio, alkylsulfonyl, alkylaminosulfonyl, NO2, (un)substituted amino, carbamoyl, etc.; n = 0-5; or pharmaceutically acceptable salts thereof] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase (no data). For example, 6-chloronicotinic acid was condensed with N,O-dimethylhydroxylamine·HCl (96%). Treatment of the amide with (i-Bu)2AlH gave the aldehyde (24%), which was coupled with (phenyl)(p-tolylsulfonyl)methylisocyanide to afforded 2-chloro-5-(4-phenyloxazol-5-yl)pyridine (71%). Conversion to the hydrazine (100%), followed by coupling with isobutyryl chloride and cyclization using POCl3 (32%), produced II. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT **459447-61-1P**, 3-Isopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-64-4P**, 3-Ethyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-66-6P**, 3-Cyclopropyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-67-7P**, 3-Cyclobutyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-69-9P**, 3-Difluoromethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-71-3P**, 3-(Isoxazol-5-yl)-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-72-4P**, 6-(4-Phenyloxazol-5-yl)-3-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridine **459447-73-5P**, 3-Cyclobutyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-74-6P**, 3-Cyclopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-75-7P**, 3-Ethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-76-8P**, 3-Ethyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-77-9P**, 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-78-0P**, 3-Cyclobutyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-79-1P**, 3-Isopropyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-80-4P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-82-6P**, 3-Cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-83-7P**, 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

459447-84-8P, 3-Isopropyl-6-(2-methyl-4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-88-2P**, 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]-pyridine **459447-89-3P**, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]acetic acid ethyl ester **459447-90-6P**, 3-(2-Chlorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-91-7P**, 6-[4-(2-Fluoro-5-methylphenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-92-8P** **459447-93-9P**, 3-(2-Fluorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-94-0P**, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]dimethylamine **459447-95-1P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459447-96-2P**, 6-[4-(3-Chloro-4-fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-97-3P**, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-98-4P**, 3-(2-Chlorophenyl)-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459448-00-1P**, 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459448-01-2P**, 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459448-02-3P**, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-inflammatory agent; prepn. of (phenylheterocyclyl)triazolopyridines as anti-inflammatory agents)

RN 459447-61-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-64-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 459447-66-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-67-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-69-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(difluoromethyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-71-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(5-isoxazolyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459447-72-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-phenyl-5-oxazolyl)-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 459447-73-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-74-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-75-7 CAPLUS

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-76-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-77-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-78-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459447-79-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-80-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-82-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459447-83-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459447-84-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(2-methyl-4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-88-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459447-89-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine-3-acetic acid, 6-[4-(4-fluorophenyl)-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 459447-90-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-91-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2-fluoro-5-methylphenyl)-5-oxazolyl]-

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459447-95-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459447-96-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-chloro-4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-97-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) (9CI) (CA INDEX NAME)



RN 459447-92-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 459447-93-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-fluorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-94-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridin-3-amine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459447-98-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459448-00-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459448-01-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 459448-02-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    52.55     375.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.30      -7.30

STN INTERNATIONAL LOGOFF AT 10:29:47 ON 15 NOV 2005
```